Main Article Content

Doaa Ali Mohammad Sharaf EldeenAbdelgawad Elmetwaly Abdelgawad

Keywords

Abstract

Background and aim of the work: to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine combination in patients who had recurrent platinum resistant ovarian cancer. Patients and method: twenty one patients with recurrent platinum resistant ovarian cancer were designated to receive vinorelbine 25 mg/m2 plus gemcitabine 1 gm/m2 on 1st and 8th day of each 21 – day cycle. Results: The Median age was 56 years (range 38-67). One patient (4.8%) achieved complete response and 5 patients (23.8%) had partial response with an overall response rate 28.57%. Median time to progression was 4 months and median overall survival was 11 months. Toxicity was modest and generally tolerated. Nine events (42.85%) of grade 3 hematological toxicity and only one event (4.57%) grade 3 non hematologic toxicity were observed. Conclusion: The combination of gemcitabine and vinorelbine is a moderately active regimen in recurrent platinum resistant ovarian cancer with an acceptable toxicity rating it as an option in treatment of such disease.

All Journal articles from 2019 onwards are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, NC SA 3.0 https://creativecommons.org/licenses/by-nc-sa/3.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for non-commercial purposes, given appropriate attribution to the original article.

The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, NC SA version 3.0 (https://creativecommons.org/licenses/by-nc-sa/3.0/)

Upon submission, author(s) grant the Journal the license to publish their original unpublished work, within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.

The publisher retains the commercial rights on printed copies on request.

Reproductions with commercial intent will require written permission and payment of royalties.

SUBMISSION NOT AVAILABLE

THE EUROPEAN JOURNAL OF ONCOLOGY IS CURRENTLY UNDER RENOVATION AND AT THE MOMENT THE JOURNAL CAN NOT ACCEPT ANY NEW SUBMISSION. THANK YOU FOR YOUR COOPERATION